Halozyme Therapeutics Inc (HALO)

[rod5247]

Giovanni Caforio - Bristol-Myers Squibb Co.

Gregg, let me just add on that, because I think it's really important as part of our strategy as a company, given the number of assets we have in development, the potential for combinations, to continue to lead in terms of innovating delivery models. Murdo's comments are really important in the U.S. A significant part of our business is outside of the U.S., where the constraints with resources at hospital level and the number of distribution on oncology sites is, in some cases, a limiting factor.

The other thing I would say is that one of our key priorities across multiple tumor types has really been, from the beginning, to accelerate immuno-oncology into the adjuvant setting. And clearly, when you look at patients that are healthy and (58:09) in the adjuvant setting, clearly, thinking about different delivery models is going to be very important for us as well.

Two post from BMY Q3 transcript
https://seekingalpha.com/article/4117040-bristol-myers-squibb-bmy-q3-2017-results-earnings-call-transcript